Medtronic InFuse Sales Flat In Q2; Firm’s Spine Business Still Struggling
This article was originally published in The Gray Sheet
Executive SummaryMedtronic is exploring alternative distribution channels in oral maxillofacial and trauma markets to grow its struggling InFuse bone graft franchise, the firm said during its Nov. 18 fiscal second-quarter earnings call
You may also be interested in...
Illumina rejects Roche’s increased bid. Medtronic settles shareholder suit over Infuse. HeartWare buys WorldHeart for $8 million. More news briefs.